GLP-1 Signaling in Truncally Vagotomized Subjects

University of Copenhagen24 enrolled

Overview

Investigation of the importance of vagal signaling for the glucohomeostatic effects of GLP-1. The study will include physiological studies of truncally vagotomized participants and matched controls.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Physiology

Interventions

Tablet Sitagliptin 100mg (evening before and morning of experiments)DRUG

On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).

Intestinal Fructose administrationOTHER

On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube

Eligibility

Sex: MALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Truncally vagotomized individuals: Inclusion Criteria: * Normal fasting plasma glucose * Normal haemoglobin concentration * Cardiaresection with a pyloroplasty * Informed consent Exclusion Criteria: * Diabetes mellitus * Disposition for diabetes mellitus * Intestinal disease (apart from cardia resection+pyloroplasty) * Disposition of inflammatory bowel disease * Intestinal resection (apart from cardia resection+pyloroplasty) * Body mass index (BMI) \> 27,5 kg/m2 * Tobacco use * Nephropathy (se-creatinine\> 130 µM and/or albuminuria) * Liver disease (ALAT and/or ASAT \>2 × refference value) * known heart condition * medicinal use, that may not be paused for 12 hours * Obstipation * swallowing difficulties * previous problems with intestinal tube placement * Latex allergy * Fructose malabsorption * Known diseases in the pharynx * Previous facial or cranial fractures * Sinusitis * Bleeding diathesis Matched controls: Inclusion Criteria: * Normal fasting plasma glucose * Normal haemoglobin concentration * Informed consent Exclusion Criteria: * Cardiaresection with a pyloroplasty * Diabetes mellitus * Disposition for diabetes mellitus * Intestinal disease (apart from cardia resection+pyloroplasty) * Disposition of inflammatory bowel disease * Intestinal resection tarmresektion (apart from cardia resection+pyloroplasty) * Body mass index (BMI) \> 27,5 kg/m2 * Tobacco use * Nephropathy (se-creatinine\> 130 µM and/or albuminuria) * Liver disease (ALAT and/or ASAT \>2 × refference value) * known heart condition * medicinal use, that may not be paused for 12 hours * Obstipation * swallowing difficulties * previous problems with intestinal tube placement * Latex allergy * Fructose malabsorption * Known diseases in the pharynx * Previous facial or cranial fractures * Sinusitis * Bleeding diathesis

Locations (1)

Department of Surgery C, Rigshospitalet

Copenhagen, Denmark

RECRUITING

Outcomes

Primary Outcomes

Insulin secretion

Evaluated by c-peptide and insulin levels - Plasma collected up to 4 hours will be analyzed for peptide hormones

Time frame: up to 4 hours

Secondary Outcomes

Glucagon secretion

Plasma collected over 4 hours will be analyzed for peptide hormones

Time frame: 4 hours

Glucose levels

Plasma collected over 4 hours will be analyzed for glucose

Time frame: 4 hours

Pancreatic Polypeptide levels

Plasma collected over 4 hours will be analyzed for peptide hormones

Time frame: 4 hours

GIP secretion

Plasma collected over 4 hours will be analyzed for peptide hormones

Time frame: 4 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.